Literature DB >> 3504553

Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm.

M F Brin1, S Fahn, C Moskowitz, A Friedman, H M Shale, P E Greene, A Blitzer, T List, D Lange, R E Lovelace.   

Abstract

Medical treatment of dystonia usually results in an incomplete response and is frequently unsuccessful. Peripheral surgical therapy is available for some focal dystonias, but may only offer temporary relief and may have unacceptable complications. We have used local injections of botulinum toxin into the appropriate muscles for treatment of disabling focal or segmental dystonia in 93 patients with torticollis, blepharospasm, oromandibular dystonia (OMD), limb dystonia, lingual dystonia, and dystonia adductor dysphonia, in addition to four patients with hemifacial spasm. Significant relief of motor symptoms was seen in 69% of the patients with blepharospasm and 64% of patients with torticollis; 74% of the latter group with pain experience relief. Relief of symptoms was noted in most patients with OMD and limb dystonia, and all with lingual dystonia, dystonic adductor spastic dysphonia, and those with hemifacial spasm. Benefit averaged 2 1/2-3 months initially; however some patients experienced longer relief with subsequent injections. Adverse effects were transient, although 2 patients developed antibodies against the toxin, and we documented evidence for distant effects in others. This approach of chemically weakening contracting muscles in focal dystonia offers many advantages over pharmacotherapy and surgical therapy. Additional experience is needed to explore the proper doses, and potential for long term adverse effects.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3504553     DOI: 10.1002/mds.870020402

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  51 in total

1.  Mechanism of Botulinum Toxin in the Relief of Chronic Pain.

Authors: 
Journal:  Curr Rev Pain       Date:  1999

2.  Treatment of spasmodic torticollis with local injections of botulinum toxin. One-year follow-up in 37 patients.

Authors:  W Poewe; L Schelosky; B Kleedorfer; F Heinen; M Wagner; G Deuschl
Journal:  J Neurol       Date:  1992-01       Impact factor: 4.849

3.  Botulinum toxin treatment in spasmodic torticollis.

Authors:  J D Blackie; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-08       Impact factor: 10.154

Review 4.  Botulinum toxin for the treatment of movement disorders.

Authors:  Mary Ann Thenganatt; Stanley Fahn
Journal:  Curr Neurol Neurosci Rep       Date:  2012-08       Impact factor: 5.081

Review 5.  Use of botulinum toxin in the neurology clinic.

Authors:  Erle C H Lim; Raymond C S Seet
Journal:  Nat Rev Neurol       Date:  2010-10-12       Impact factor: 42.937

6.  Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm.

Authors:  P Roggenkämper; W H Jost; K Bihari; G Comes; S Grafe
Journal:  J Neural Transm (Vienna)       Date:  2005-06-15       Impact factor: 3.575

7.  Neurophysiological observations on the effects of botulinum toxin treatment in patients with dystonic blepharospasm.

Authors:  J Valls-Sole; E S Tolosa; G Ribera
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-04       Impact factor: 10.154

Review 8.  Evidence based medicine on the use of botulinum toxin for headache disorders.

Authors:  W J Schulte-Mattler; E Leinisch
Journal:  J Neural Transm (Vienna)       Date:  2007-11-12       Impact factor: 3.575

Review 9.  Therapeutic use of botulinum toxin in migraine: mechanisms of action.

Authors:  Roshni Ramachandran; Tony L Yaksh
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

10.  Treatment of cervical dystonia hand spasms and laryngeal dystonia with botulinum toxin.

Authors:  A J Lees; N Turjanski; J Rivest; R Whurr; M Lorch; G Brookes
Journal:  J Neurol       Date:  1992-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.